Results 131 to 140 of about 5,633 (170)
Some of the next articles are maybe not open access.
An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis
International Journal of Antimicrobial Agents, 2022Jos H Beijnen, Thomas P C Dorlo
exaly
Current opinion in investigational drugs (London, England : 2000), 2003
Zentaris (formerly Asta Medica) has developed and launched miltefosine, a phospholipid derivative, in various European countries [173324], [254947] and in Brazil in 1997 [332428], [366795] as a treatment for breast cancer. As of January 2002, phase III trials for treatment of leishmaniaisis were ongoing [435767].
openaire +1 more source
Zentaris (formerly Asta Medica) has developed and launched miltefosine, a phospholipid derivative, in various European countries [173324], [254947] and in Brazil in 1997 [332428], [366795] as a treatment for breast cancer. As of January 2002, phase III trials for treatment of leishmaniaisis were ongoing [435767].
openaire +1 more source
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use
Drug Resistance Updates, 2006Simon L Croft +2 more
exaly